Massivemarkets

KROS

Keros Therapeutics, Inc. Common Stock

Nasdaq · usd

$11.08-0.31 (-2.72%)
At close · 15-minute delayed
$11.02-0.06 (-0.54%)
As of 4:25:24 PM EST on Nov 20, 2026 · After hours

Keros Therapeutics, Inc. Common Stock (KROS) trades at $11.08 (-2.72%) as of 4:25:24 PM EST on Nov 20, 2026, -2.38% over the past month. Market cap is $223.52M, with 7.1 days to cover in short interest.

Stock performance

How Keros Therapeutics, Inc. Common Stock (KROS) stock has performed from one day to one year, with its 52-week range.

-2.38%
-$0.27 over 1D
$11.08$11.24$11.39$11.559:30 AM11:05 AM12:50 PM2:25 PM4:00 PM$11.08
1D
-2.72%
1W
+7.57%
1M
-2.38%
YTD
-45.58%
1Y
-36.29%
52-wk range
$8.98 – $22.55

Key statistics

Today's trading snapshot for KROS: day range, open, previous close, volume and market cap.

Day range
$10.95 – $11.59
Open
$11.18
Prev close
$11.39
Volume
208.69K
Market cap
$223.52M
Shares out
19.62M

Valuation and profitability ratios: P/E, P/S, ROE

Valuation and profitability ratios for Keros Therapeutics, Inc. Common Stock: P/E, P/S, P/B, ROE and more.

P/E
—
P/S
5.48
P/B
0.80
P/FCF
—
ROE
-22.1%
ROA
-20.1%
Debt/Equity
0.00
Div yield
0.00%

As of Nov 19, 2026

8-K filings

Material corporate events Keros Therapeutics, Inc. Common Stock has disclosed to the SEC on Form 8-K.

  • On November 16, 2026, Keros Therapeutics, Inc. ... issued a press release announcing that the board of directors of the Company has approved a new stock repurchase program for up to $5 million of the Company's common stock.

  • On November 5, 2026, Keros Therapeutics, Inc. (the "Company") issued a press release announcing its recent business highlights and financial results for the quarter ended September 30, 2026.

  • Investor presentationNov 5, 2026

    On November 5, 2026, Keros Therapeutics, Inc. (the "Company") updated its corporate presentation for use in meetings with investors, analysts and others. The presentation is available through the Company's website and a copy is attached as Exhibit 99.1 to this Current Report on Form 8-K.

  • Licensing agreementSep 29, 2026

    The Company will receive a $20 million development milestone payment under the terms of the license agreement of elritercept with partner Takeda Pharmaceuticals U.S.A., Inc.

  • Based on its current operating plans, the Company anticipates that its cash and cash equivalents as of June 30, 2026, after giving effect to (i) the $20 million development milestone received under the license agreement with Takeda and (ii) the Stock Repurchase, will be sufficient to enable it to fund its operating expenses and capital expenditure requirements into the second half of 2028.

KROS short interest

How heavily KROS is shorted: shares short, days to cover and average daily volume.

Days to cover
7.1
Short interest
1.09M
Avg volume
153.86K

As of · reported to FINRA twice monthly.

KROS news

The latest news and headlines about Keros Therapeutics, Inc. Common Stock (KROS).

Frequently asked questions

What is the Keros Therapeutics, Inc. Common Stock (KROS) stock price today?

Keros Therapeutics, Inc. Common Stock (KROS) is trading at $11.08 (-2.72% on the day) as of 4:25:24 PM EST on Nov 20, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

What is Keros Therapeutics, Inc. Common Stock?

Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs.

What is the short interest in KROS?

As of Oct 30, 2026, KROS has 1.09M shares short and 7.1 days to cover.

What exchange is KROS listed on?

Keros Therapeutics, Inc. Common Stock (KROS) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.

Build with AI

Build an analysis of KROS with your agent

Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.

Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a KROS analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.

Live market data from the Massive API and MCP.Get a free API key

Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.